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ABSTRACT
Mucopolysaccharidosis (MPS) IIIB is a lysosomal storage disease due to 
the deficiency of the enzyme α-N-acetylglucosaminidase (NAGLU) 
required for heparan sulfate degradation. Since perturbation of lysosomal 
homeostasis represents an important cause of cardiomyocyte dysfunction 
in cardiovascular diseases, we generated a model of the MPS IIIB by 
silencing NAGLU gene expression in H9C2 rat cardiomyoblasts. 
NAGLU-depleted H9C2 exhibited accumulation of abnormal lysosomes 
and a hypertrophic phenotype. Through a phospho-receptor tyrosine 
kinase array, we found the specific activation of the epidermal growth 
factor receptor (EGFR) in NAGLU-depleted H9C2 compared to control 
cells. The pretreatment of NAGLU-depleted H9C2 with the specific 
EGFR inhibitor AG1478 caused the reduction of both lysosomal 
aberration and cellular hypertrophy. Similar results were obtained when 
NAGLU-depleted H9C2 were treated with PD98059, a selective inhibitor 
of MEK/ERK downstream targets of EGFR. Furthermore, we found 
increased phosphorylation levels of c-Src in NAGLU-depleted H9C2 
where c-Src perturbation affected the hypertrophic response. However, c-
Src phosphorylation remained unaffected after treatment of NAGLU-
depleted H9C2 clones with AG1478, posing c-Src phosphorylation 
upstream EGFR activation. Finally, the heparin-binding EGF-like growth 
factor (HB-EGF) protein resulted to be up-regulated in NAGLU-depleted 
H9C2, and its silencing caused a reduction of the hypertrophic response. 
These results demonstrate that both c-Src and HB-EGF may contribute to 
the hypertrophic phenotype of NAGLU-depleted cardiomyoblasts by 
activating EGFR signaling, and suggest that the inhibition of EGFR 
pathway might represent an effective therapeutic strategy for the cure of 
MPS IIIB cardiac disease.
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1. INTRODUCTION
1.1 Lysosomes and lysosomal storage diseases
Lysosomes are cytoplasmic cellular organelles found in all nucleated 
eukaryotic cells. They are delimited by a single-layer lipid membrane and 
have an acidic internal pH of 4.5-5.0 that is maintained by an adenosine 
triphosphate (ATP)-dependent proton pump. Morphologically, the 
lysosome is a highly heterogeneous organelle since the size, shape, and 
number per cell are variable depending on the cell type. It may be spheric, 
ovoid, or occasionally tubular in shape, and may vary between 0.1 to 2 
μm in size. The primary cellular function of the lysosome is the 
degradation and recycling of several macromolecules, including nucleic 
acids, proteins, glycosaminoglycans (GAGs), oligosaccharides, 
sphingolipids, and other lipids. Proteins, which must be degraded into the 
lysosomes, are introduced into these organelles by means of various 
mechanisms involving endocytosis, autophagy and direct transport 
through the lysosomal membrane. The endosomal/lysosomal system 
(E/L), together with the ubiquitin-proteosome system (UPS) and 
autophagosome, represents an important metabolic center for substrates 
degradation, by influencing various cellular functions, signal transduction 
and the regulation of genes expression (Figure 1).
Figure 1. Main functions of the lysosome and their relationship 
with key cellular processes. From Settembre C., et al. 2013. Nature
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Lysosomes are involved in a wide range of cellular processes, 
including cell signaling, antigen presentation, immunity, plasma 
membrane repair, or initiation of apoptosis. They are crucial for the 
maturation of phagosomes to phagolysosomes during phagocytosis, 
which is a fundamental mechanism during cellular pathogen defense. 
During exocytosis, lysosomes fuse with plasma membrane in response to 
increased concentration of cytosolic Ca2+ providing an extra membrane 
for wound repair (Reddy A. et al., 2001; Rodriguez A. et al., 1997). 
Lysosomal damage seems to be an early event in the apoptotic signaling 
cascade prior to increase the permeability of the mitochondrial membrane 
and the release of apoptogenic factors. Lysosome-mediated apoptosis also 
involves the lysosomal cathepsins. These proteolytic enzymes are able to 
cleave pro-apoptotic molecules and caspases, acting as mediators between 
lysosomes and mitochondria (Conus S. et al., 2008). Lysosomal 
cathepsins are also required for the generation of antigenic peptides from 
exogenous proteins, and are involved in the trafficking and maturation of 
the major histocompatibility complex (MHC) class II (Chapman H.A., 
1998; Driessen C. et al., 1999), thus playing a role in adaptive immunity. 
In addition, intracellular cholesterol homeostasis is controlled through a 
lysosomal transporter, the Niemann-Pick, Type C1 protein (NPC1). 
Lysosomal Storage Diseases (LSDs), with an incidence of 1/7000 
birth, are genetic disorders caused by mutations in genes encoding for 
lysosomal enzymes or transporters. The deficeincy of these proteins 
results in the accumulation of one or more undegraded substrates in the 
lysosomes of different orgnas leading to cell death (Platt F.M and 
Walkley S.U., 2004) (Figure 2).
Figure 2: Lysosomes enlargement in MPS-affected mouse liver 
sections compared to a wilde-type mouse. From Platt F.M., et al., 2004
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Although the cytotoxicity of the enlarged lysosomes is still 
considered the primary cause of the LSDs, recent studies have revealed 
new pathogenetic mechanisms (Walkley S.U et al., 2009). Among these, 
autophagy deregulation is considered the major causes of LSDs together 
with dysfunctions of the UPS system (Settembre C. et al., 2008). These 
evidences support the role of the lysosome as a central element between 
endocytic flows and metabolic recovery.
1.2 Glycosaminoglycans and their catabolism
Glycosaminoglycans (GAGs) or mucopolysaccharides are linear 
polysaccharidic chains formed by diacidic units of an exosamine 
(glucosamine or galactosamine) and an uronic acid (glucuronic or 
iduronic acid), with the exception of keratan sulfate in which the uronic 
acid is replaced by an hexose (galactose). The GAGs, based on the nature 
of the esosamine residues, are classified into two groups: 1) 
glucosaminoglycans which include hyaluronic acid (HA), keratan sulfate 
(KS), eparan sulfate (HS) and heparin; 2) galactosaminoglycans which 
comprise chondroitin sulfate (CS) and dermatan sulfate (DS) (Figure 3).
F i g u r e 3: S t ru c t u r e s o f g a l a c t o s a m i n o g l y c a n s a n d 
glucosaminoglycans. From Deyan M., et al., 2015. JBC
Monosaccharide units are bound together by a glycosidic bond 
between the hydroxyl group of the anomeric carbon (C-1) of a uronic acid 
and the hydroxyl group of an hexosamine, forming a long chain GAG. 
The high variety of these macromolecules is due to the presence of the 
sulfate groups on carbon atom 4 and 6 and the acetylation of the amino 
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group of the hexosamine. The molecular weight of the GAG ranges 
between 50,000 and 4,000,000 Dalton (Da). Due to the high content of 
carboxyl groups (-COO-) and esterified sulfate groups (-O-SO3-), GAGs 
are polyanions wherein the number of negative charge per unit of 
disaccharide is 1 in the hyaluronic acid up to 4 in the heparin. Most of the 
fragments and monosaccharides generated by GAG degradation, 
occurring in the lysosomes, return in the cell biosynthetic pathways. The 
degradation process is finely regulated and mediated by hydrolytic 
enzymes that are substrate-specific, in accordance with sugar 
stereoisomers, with the type of the glycosidic bond, and with the pH of 
the lysosomal compartment. The first class of these enzymes includes 
esoglycosidases that catalyze the release of the specific monosaccharide 
at the non-reducing end of the oligosaccharide chain. The 
endoglycosidases, in turn, hydrolyze specific glucidic sequences within 
the biopolymer, generating fragments of about 10 kDa. Sulphatases, 
exosaminidases and glucuronidases also co-operate at the hydrolysis 
process (Table 1).
Enzyme Reaction
Iduronate-2-sulfatase Hydrolysis of the 2-sulfate group in L-
iduronate of DS and HS
 -iduronidase Hydrolysis of not sulfated iduronic bond in 
DS
GalNAc-4-sulphatase Hydrolys is of 4-sul fa te group of 
GalNAc4S and GalAGs
GalNAc-6-sulphatase Hydrolys is of 6-sul fa te group of 
GalNAc6S and D-gal
 -glucuronidase Removal of residual of  -GlcA
Table1: Lysosomal enzymes involved in degradation of GAGs.
GAGs are often associated to a protein core, giving rise to the 
proteoglycans (Figure 4), which constitute the major components of the 
extracellular matrix and of the connective tissue (Chaplin et al. 1986).
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Figure 4: The three main classes of cell-surface heparan sulfate 
proteoglycans. From Xinhua L., 2004. Development
Proteoglycans participate in a plethora of cellular functions, both at 
the cell surface and intracellularly, and are thus indispensable for many 
essential processes including morphogenesis, neuronal development, 
tumor formation, and pathogen uptake (Mikami T. and Kitagawa H., 
2013; Sarrazin S. et al., 2011).
1.3 Heparan sulfate proteoglycans (HSPGs)
HSPGs are the major determinants of how cells sense, integrate and 
respond to their environment. They mediate multiple biological processes 
as receptors or co-receptors for many protein ligands in the extracellular 
matrix (ECM) (Esko J.D. and Selleck S.B., 2002). HSPGs primarily 
regulate interactions between adjacent cells or between cells and the 
ECM, and they control cell adhesion, proliferation and migration. 
Importantly, HSPGs cooperate with integrins and the major class of ECM 
receptors to activate intracellular signaling cascade (Lopes C.C. et al., 
2006) (Figure 5).
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Figure 5: HSPGs-integrin cooperation. HSPGs modulate growth 
factor signaling (A) and participate in cell adhesion (B). (A) Formation of 
a ternary complex between HS, FGF and FGFR and subsequent signal 
transduction are represented. (B) Focal adhesion in which integrins and 
HSPGs cooperate to connect the ECM and the cytoskeleton is 
represented. From Lopes et al., 2006.
HSPGs ligands include ECM constituents (e.g. fibrin, fibronectin, 
laminin, and various types of collagen), cell adhesion molecules (L- 
selectin, N-CAM), and soluble growth factors (EGF, FGF, insulin-like 
growth factor-2, platelet-derived growth factor, transforming growth 
factor, vascular endothelial growth factor, hepatocyte growth factor). In 
addition, HS chains possess the ability to bind cytokines such as 
interleukin (IL)-5, IL-6, IL-8, IL-10, or tumor necrosis factor (TNF) 
(Whitelock J.M. and Iozzo R.V., 2005), playing a role in cytokine action 
regulation.
HSPGs have also important neurobiological functions. They play a 
role in the establishment and maintenance of neuronal connections and 
are therefore crucial for both CNS development and plasticity (Murrey H. 
and Hsieh-Wilson L.C., 2008). In neurons, extracellular HS regulates 
neural cell migration, axons growth and guidance, neuronal polarity and 
neurite outgrowth (Bovolenta P. and Fernaud-Espinosa I., 2000). These 
effects are mediated by growth factors (e.g., FGFs), secreted morphogens 
(e.g., Wnt or Shh), repellents and attractants (e.g. Slit, Netrin, or 
Semaphorins and Ephrins) (Hu H. et al., 2001; Lin L. et al., 2005).
Apart from sequestration of bioactive molecules, transmembrane 
(syndecans) and phospholipid-anchored (glypicans) HSPGs have a co-
receptor role in which the proteoglycan, in concert with other cell surface 
molecules, comprises a functional receptor complex that binds the ligand 
and mediates its action (Kjellen L. and Lindahl U., 199). Cleavage of HS 
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side chains is therefore expected not only to alter the integrity of the 
ECM, but also to release HS-bound biological mediators.  ECM-
remodeling enzymes deeply affect cell and tissue functions. Heparanase is 
an endo- -D-glucuronidase capable of cleaving HS side chains at a 
limited number of intrachain sites, yielding HS fragments of small size 
(~5-7 kDa) (Freeman C. and Parish C.R., 1998). Heparanase activity has 
long been detected in a number of cell types and tissues. Importantly, 
heparanase activity correlates with the metastatic potential of tumor-
derived cells, attributed to enhanced cell dissemination as a consequence 
of HS cleavage and remodeling of the ECM barrier (Parish C.R. and 
Freeman C., 2001). In spite of its localization into a highly active protein 
degradation environment such as the lysosome, heparanase exhibits a 
halflife of about 30 hours (Gingis-Velitski S. and Zetser A., 2004). 
Residence and accumulation of heparanase in late endosomes and 
lysosomes may indicate that the enzyme acts in the physiological turnover 
of cellular HSPGs (Fuller M. and Chau A., 2005). Since the enzyme is not 
readily accessible to its extracellular substrate, regulatory mechanisms by 
which intracellular lysosomal heparanase is secreted in response to local 
or systemic stimuli should exist.
1.4 Mucopolysaccharidoses
Mucopolysaccharidoses (MPSs) are a group of lysosomal diseases 
caused by the lack of enzymes responsible for the catabolism of 
mucopolysaccharides (Neufeld E.F. and Muenzer J., 2001). MPSs are 
autosomal recessive disorders, with the exception of the MPS II which is 
transmitted as an X-linked tract. MPS I (Hurler Syndrome) is caused by 
the deficiency of the  -L-iduronidase (IDUA) enzyme, whose gene 
cause the HS and DS lysosomal accumulation. The accumulation of the 
same metabolites is found in the MPS II (Hunter syndrome) caused by 
mutations in the idronate-2-sulphatase enzyme (IDS) gene. MPS III 
(Sanfilippo syndrome) is subdivided into 4 subtypes, depending on the 
missing enzyme: eparan-N-sulphatase (SGSH) in MPS IIIA (Sanfilippo 
syndrome type A), N-acetylglucosaminidase (NAGLU) in MPS IIIB 
(Sanfilippo syndrome type B),  -glucosaminide-N-acetyltransferase 
(HGSNAT) in MPS IIIC (Sanfilippo syndrome type C), and N-
acetylglucosamine-6-sulphatase (GNS) in MPS IIID (Sanfilippo 
syndrome type D). All these subtypes of MPS III are characterized by the 
HS lysosomal accumulation. MPS IV (Morquio syndrome) is divided into 
two subtypes: MPS IVA (Morquio syndrome type A) due to the 
deficiency of the N-acetylgalactosamine-6-sulfate sulphatase (GALNS) 
enzyme, and MPS IVB (Morquio syndrome type B) resulting from the 
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deficiency of  -galactosidase ( -GAL). In both MPS IV subtypes the 
lysosomal accumulation products are CS and DS. MPS VI (Maroteaux-
Lamy syndrome) is caused by the deficiency of the N-acetylglucosamine-
4-sulphatase enzyme (arylsulfatase B, ARSB), whose gene encodes for a 
DS degradation enzyme. MPS VII (Sly syndrome), in which the 
lysosomal accumulation of HS and DS is detected, is caused by the lack 
of  -D-glucuronidase (GUSB) enzyme. Finally, the most recently 
identified MPS IX is caused by hyaluronidase enzyme deficiency 
(HYAL1) and it is characterized by the lysosomal accumulation of 
hyaluronic acid, the only GAG that is not sulfated (Figure 6).
Figure 6: Classification of MPSs according to the missing enzyme 
and the lysosomal accumulated product.
MPSs exhibit a variable phenotype in both severity and progression, 
which include skeletal malformations, dimorphic facial features, 
organomegaly, and motor and neurological defects. In some forms, such 
as MPS I, MPS II and all subtypes of MPS III, mental retardation is the 
main clinical symptom and it is associated with a severe disability. 
Skeletal alterations, however, are typical of MPS IV and MPS VI.
Numerous studies in vivo have been carried out over the last years 
using the available animal models to explain the pathogenetic bases of 
MPSs. Like the other lysosomal diseases, many experimental trials have 
also demonstrated the involvement of an inflammatory response. The up-
regulation of many proteins involved in inflammation, especially 
cytokines and proteases, has been demonstrated in animal models of MPS 
I (Ma X. et al, 2008; Metcalf J.A. et al., 2010), MPS VI (Simonaro C.M. 
et al, 2001-2005-2008-2010) and MPS VII (Simonaro C.M. et al, 2005-
2008-2010; Richard et al., 2008; Metcalf J.A.et al., 2010). This up-
regulation causes structural alterations in connective tissue/cartilage, 
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compromises elastogenicity and, finally results in skeletal and articular 
alterations. At least for MPS VI and VII, the up-regulation of the 
inflammatory response seems to be related to the activation of Toll-like 
receptor 4 signal transduction mechanisms (TLR4) (Simonaro C.M. et al, 
2010). In MPS I and VII, alterations of the levels of the Fibroblast 
Growth Factor 2 (FGF2) and neurotropin have been decteted in vitro (Pan 
C. et al., 2005) and in vivo (Richard et al, 2008) and associated with the 
patogenesis of the diseases. Oxidative stress markers were observed in 
MPS I and II patients (Pereira V.G. et al., 2008; Hamano K. et al., 2008) 
and murine MPS I (Reolon G.K. et al, 2009). In addition, impairement of 
autophagy, with a lack of fusion between autophagosomes and lysosomes, 
has been demonstrated in the murine models of MPS IIIA and MPS VI as 
well as in another lysosomal disease like the Multiple Sulfate Deficiency 
(MSD) (Settembre C. et al., 2008; Ballabio A. et al., 2009). Other 
mechanisms may be involved in the pathogenesis of MPS: for example, it 
is known that the accumulation of unfolded or incorrectly folded protein 
usually generates endoplasmic reticulum (ER) stress resulting in a 
response characterized by changes in specific proteins, attenuation of 
translation, induction of ER chaperonins and degradation of non-folded 
proteins (Jellinger K.A. et al, 2009). In particular, cell homeostasis 
alterations that relate to the folding of proteins in the ER activate a signal 
transduction process known as the “Unfolded Protein Response” (UPR); 
initially cytoprotective, the UPR triggers an apoptotic cascade under 
conditions of prolonged or aggravated ER stress. ER stress is considered a 
possible cause of neurodegeneration in one of the most well known 
tauopathies, such as Alzheimer's disease, and in the lysosomal 
accumulation disorders (Hoozemans J.J. et al, 2009; Wei S.J. et al., 2008).
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1.5 Mucopolysaccharidosis IIIB
Mucopolysaccharidosis IIIB (MPS IIIB) is a subtype of the MPS III 
caused by mutations in the gene encoding for the lysosomal enzyme 
NAGLU involved in the degradation of HS (Figure 7).
Figure 7: Heparan sulfate degradation pathway.
The disease has an incidence of 1 on 235,000 live births (Meikle P.J. 
et al., 1999) and it is characterized, from a clinical point of view, by a 
relatively mild somatic manifestation and by severe neurological 
disorders. The onset of clinical symptoms occurs between 2 and 6 years 
of age. Affected childrens, at birth seem appearently normal, but their 
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condition progressively worsen, and they develop serious neurological 
manifestations that include hyperactivity, aggressive behavior and sleep 
disorders, with rapid deterioration of social and adaptive abilities 
(Neufeld E.F. and Muenzer J., 2001). The neuropsychiatric abnormalities 
are divided into three phases (Cleary M.A. and Wraith J.E., 1993; Bax 
M.C. and Colville G.A., 1995): affected children between 1-4 years of 
age show only development delay, from 4 years onwards they show 
serious behavioral disorders, and, finally, physical deterioration and loss 
of strength. Life expectancy for subjects affected by the severe form of 
the disease is up to adolescence, although a higher survival characterizes 
patients with milder forms.
The NAGLU gene extends for 8.2 Kb from the site of initiation to the 
polyadenylation site, with 6 exons whose size ranges from 86 bp to 1452 
bp. The cDNA encodes for a protein of 720 amino acids with 6 potential 
N-glycosylation sites (Zhao H.G. et al., 1996; Weber B. et al., 1996). 
NAGLU protein was firstly purified from placenta (Weber B. et al., 
1996), liver (Sasaki T. et al., 1991) and urine (Salvatore D. et al., 1984), 
and its biosynthesis and maturation has been studied in skin fibroblasts 
(von Figura K. et al., 1984) and in human carcinoma cells (Di Natale P. et 
al., 1985). The molecular weight of the protein is 80-86 kDa for the 
precursor form, 77 kDa for the intermediate form and 73 kDa for the 
mature form. Recombinant NAGLU protein was expressed in CHO cells 
(Chinese Hamster Ovary cells), showing to be poorly phosphorylated in 
these cells (Yogalingam G. et al., 2000). The ineffective phosphorylation 
of the recombinant NAGLU protein in CHO cells does not allow its 
incorporation by MPS IIIB cells in vitro (Zhao K.W. and Neufeld E.F., 
2000; Weber B. et al., 2001) and in vivo (Yu W.H. et al., 2000).
Regarding the pathogenesis of the MPS IIIB, many studies have been 
focused to understand the neuronal pathogenesis. In particular, it has been 
shown that the inflammatory process causes the activation of microglia 
and astrocytes and consequent secretion of cytokines and neurotoxic 
chemokines (Li H.H. et al, 2002; Ohmi K. et al., 2003; Villani G.R. et al., 
2007) similarly to other neurodegenerative pathologies (Myerowitz R. et 
al, 2002; Wu Y.P. and Proia R.L., 2004). In one of the first murine model 
studies, the effect of HS accumulation on neuroplasticity has been 
analyzed (Li H.H. et al, 2002). Vitry and co-workers (2009) reported that 
lysosomal accumulation of HS-oligosaccharides in MPS IIIB neurons 
activates the synaptophysin proteasome degradation, a membrane protein 
of the synaptic vesicle related to synaptic potential, with consequences on 
components of these vesicles. More recently, the same group has 
suggested that the build up of vesicles, Golgi disorganization, and Golgi 
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biogenesis alterations may be involved in the dysfunction and neuronal 
death in MPS IIIB (Vitry et al., 2010). 
1.6 The murine model of mucopolysaccharidosis IIIB
For the MPS IIIB, as for other MPS, a murine model (NAGLU -/-) of 
the disease is available. It has been obtained by genetically modifying the 
exon 6 of the NAGLU gene (Li H.H. et al., 1999): a 852 bp fragment in 
the exon 6 has been replaced by an expression cassette containing 
Neomycin (NEO) gene. NAGLU-/- mice in the first months of life appear 
to be normal and healthy; both homozygous males and females are fertile 
up to six months of age and survive until 8-12 months of life. As they get  
older, NAGLU-/- mice become visibly ill, with weight loss, crawling hair, 
skin ulcers around the genital organs, and have difficulty in walking. The 
GAGs accumulate in the murine model, especially in the liver and kidney, 
in smaller amounts in the lung, spleen, thymus, heart, and brain, where 
there is also a secondary accumulation of gangliosides GM2 and GM3. In 
all organs, especially in the brain, the cells that most accumulate GAGs 
are those of the phagocytic system. 33 days after birth, vacuolate 
macrophages are found in many organs such as spleen, liver, lymphnodes, 
kidney, lung, skin, and brain. Neurons appear severely affected and 
various types of lesions are observed, especially in the cerebellum, in the 
Purkinje cells and in the cerebellar nuclei containing one or more 
inclusions visible with hematoxylin/eosin and with Shiff coloration. The 
murine model of MPS IIIB has sensory and behavioral deficits similar to 
that of human patients (Heldermon C.D. et al., 2007). Our research group 
recently demonstrated that NAGLU-/- mice also develop cardiac diseases 
and heart failure over time with dsyfunctions of the lysosomal-autophagic 
pathways (Schiattarella et al., 2015).
The disease in mice has a chronic and progressive course similar to 
that of human disease and, therefore, represents an excellent model for 
studying tthe pathogenesis of the MPS IIIB disease and to test new 
therapeutic approaches.
1.7 Therapies for mucopolysaccharidoses
There are limited treatments clinically available for MPSs. Symptomatic 
palliative therapies are readily available, but they only marginally 
improve the outcome of the disease. A classical therapeutic intervention 
consists of bone marrow transplantation (BMT). However, a high 
incidence of rejection limits the success of this treatment. For some 
MPSs, enzyme replacement therapy (ERT) is in clinical use, although 
ERT does not cross the blood-brain barrier and is ineffective on 
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neurological symptoms. In the recent years,gene therapy has been 
investigated, and the research group of Prof. P. Di Natale was the first one 
to demonstrate the efficacy of intravenous injection of a lentiviral vector 
containing the NAGLU gene as treatment for the MPS IIIB disease. With 
a single injection of this vector, the expression of the NAGLU transgene 
was detected in the liver, spleen, lung and heart of treated mice, and the 
recovery of enzymatic activity was obtained, resulting in the reduction of 
55% of GAG content. This reduction remained unchanged for up of 6 
months after treatment (Di Natale P. et al., 2005). Subsequently, the same 
group demonstrated that the intracranial injection of the lentiviral vector-
NAGLU has the ability to alleviate many manifestations of the disease in 
MPS IIIB mice (Di Domenico C. et al., 2009). However, other studies 
have shown the efficacy of the use of adenoviral vectors (Heldermon C.D. 
et al., 2010). The substrate reduction therapy obtained by treatment with 
genistein is still under experimental phase for the MPS IIIB: while the 
first tests did not show any visible improvements, most recently, high 
doses of genistein for 9 months given to MPS IIIB mice seem to 
significantly reduce the lysosomal substate accumulation and neuro-
inflammation in the cerebral cortex and in the hippocampus (Malinowska 
M. et al., 2009). However, studies are still in progress to identify new, 
alternative therapeutic approaches that might results to be more effective 
for the cure of MPS IIIB.
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2. AIMS
In MPS diseases, the deficits of GAG degrading enzymes with the 
consequent substrate accumulation results in multiple organ dysfunctions, 
with distinct clinical manifestations depending on the type of the lacking 
enzyme and the accumulated substrate (Neufeld E.F., 2001). Although the 
most relevant clinical symptoms in affected patients include progressive 
neurodegeneration, behavior disorders, and skeletal abnormalities 
(Neufeld E.F., 2001), cardiac involvement has been also observed, and it 
accounts for the early mortality of these patients (Braunlin E. A. et al., 
2011; Rigante D., 2002). Cardiac causes of death include heart failure, 
arrhythmias, coronary occlusion, pulmonary hypertension, and other 
cardiovascular dysfunctions. Among MPS subtypes, MPS IIIB is an 
autosomal recessive disorder caused by the deficiency of α-N-
acetylglucosaminidase (NAGLU) involved in HS degradation. The 
availability of MPS IIIB animal models (Li H.H. et al., 1999; Ellinwood 
N.M. et al., 2003) and cultured cell systems (Yogalingam G. et al., 2011; 
Lemonnier T. et al. 2011), including primary fibroblasts from MPS IIIB 
patients, has provided definite evidence that the defective lysosomal 
clearance of undigested HS is the primary cause of organ dysfunctions 
observed in the patients. 
Since an alteration of lysosomal homeostasis is an important cause of 
cardiomyocyte dysfunction in different cardiovascular diseases 
(Schiattarella G. et al., 2015), our research group previously investigated 
cardiac involvement in the MPS IIIB murine model. We demonstrated 
that NAGLU knock out mice develop heart disease, valvular 
abnormalities and heart failure (Schiattarella G. et al., 2015). Our study 
also highlighted that the cardiac defects observed in the NAGLU knock 
out mice correlate with an altered autophagic flux in the heart tissues. 
These findings prompted us to further investigate the mechanisms 
governing cardiac dysfunction in MPS IIIB. Indeed, a better 
understanding of the cellular and molecular mechanisms consequent to 
HS storage defects could be very useful to identify novel therapeutic 
targets for MPS IIIB.
The objective of my PhD project was to elucidate the link between 
abnormal lysosomal HS storage and the cardiac hypertrophic phenotype 
previously observed in the MPS IIIB mouse model. The investigation was 
carried out by generating a cellular model of the MPS IIIB through 
NAGLU gene silencing in H9C2 rat cardiomyoblasts. These cells have 
been proved to represent a relevant model to investigate mechanisms and 
consequences of cardiac pathologies, including hypertrophy (Watkins S. 
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J. et al., 2011), and differentiation (Menard G. et al., 1999; Karagiannis 
T.C et al., 2010). A phospho-receptor tyrosine kinase (RTK) array 
allowed us to identify an activated epidermal growth factor receptor 
(EGFR) on NAGLU silenced H9C2 stable clones. Overall, the results of 
this study unraveled how pertubations in the EGFR signaling pathways 
account for cellular defects that are relevant to MPS IIIB 
pathophysiology, thus providing new insights into the molecular 
mechanism by which NAGLU silencing and consequent lysosomal 
impairment cause cardiac defects in MPS IIIB disease. 
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3. MATHERIALS AND METHODS
3.1 Antibodies and chemicals.
The rabbit anti-LAMP-2 polyclonal antibody (PA1-655) was 
purchased from Thermo-Fisher; mouse anti-diphosphorylated ERK1/2 
monoclonal antibody (M8159) from Sigma Aldrich; rabbit anti-ERK1/2 
polyclonal antibody (V114A) from Promega; rabbit anti-HB-EGF 
monoclonal antibody (ab185555) and rabbit anti-NAGLU monoclonal 
antibody (ab214671) from Abcam; rabbit anti-phospho-Src (Tyr416) 
polyclonal antibody (2101), rabbit anti-Src monoclonal antibody (2109), 
rabbit anti-phospho-EGFR (Tyr1173) monoclonal antibody (4407), and 
rabbit anti-EGFR monoclonal antibody (2646) from Cell Signaling 
Technology); mouse anti-beta-actin monoclonal antibody (G043) from 
Abm: goat anti-mouse IgG polyclonal antibody conjugated to horseradish 
peroxidase (HRP) (sc-2031) and goat anti-rabbit IgG-HRP polyclonal 
antibody (sc-3837) from Santa Cruz Biotechnology.
Nuclear 4′,6-diamidino-2- phenylindole (DAPI), bovine serum 
albumin (BSA), phalloidin, and the EGFR inhibitor AG1478 [N-(3- 
chlorophenyl)-6,7-dimethoxy-4-quinazolinamine]  were purchased from 
Sigma Aldrich; SDS-PAGE reagents (Bio-Rad); the MEK inhibitor 
PD98059 [2-(2′-amino-3′- methoxyphenyl)-oxanaphthalen-4-one] from 
Calbiochem; ; fetal bovine serum (FBS) from GIBCO; LysoTracker from 
Thermo Fisher; IBAfect reagent (7-2005-050) from  IBA BioTAGnology; 
4-methylumbelliferyl-Nacetyl-α- D-glucosaminide from, Calbiochem; 
Trizol reagent from Invitrogen.
3.2 Cell cultures. 
H9C2 rat cardiomyoblasts (ATCC) were cultured in Dulbecco’s 
minimal essential medium (DMEM), 1g/L low glucose, 2 mM L-
glutamine, 1 mM sodium pyruvate, supplemented with 10% FBS, 100 
Units/ml penicillin, and 10 mg/ml streptomycin, at 37°C in a humidified 
5% CO2 atmosphere.
For stable transfection, H9C2 cardiomyoblasts were plated at a 
density of 5 × 105 cells/100-mm tissue culture dish in antibiotic-free 
DMEM containing 10% FBS. and incubated for 24 h at 37°C with 5% 
CO2. Confluent cells were transfected, using IBAfect reagent, with a pool 
of plasmids codifying for three shRNAs (188A12, 566F3, 526A3, Open 
Biosystems) targeting NAGLU or with a control plasmid codifying for a 
non- targeting shRNA. After 48 h, transfected H9C2 were selected in the 
presence of 0.4 μg/ml of puromycin. Enzymatic activity assay and RT-
PCR analysis were performed to identify the stable NAGLU-silenced 
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clones. Stable clones were grown in DMEM supplemented with 0.4 μg/ml 
of puromycin.
For transient transfections, H9C2 clones were plated at 2.5 × 105 
cells/60-mm tissue culture dish 24 h prior to transfection. Transfections 
with plasmid vectors codifying for dominant negative (DN) and wild type 
(WT) c-Src, and control vector-GFP, kindly provided by Prof. A. 
Feliciello (University of Naples Federico II, Naples, Italy) (Cardone L., et 
al., 2004), were carried out using IBAfect reagent according to the 
manufacturer's instructions. Transient transfections of H9C2 clones with 
HB-EGF siRNA siRNAID 48748, Thermo-Fisher) and with a non-
targeting siRNA were carried out using Lipofectamine RNAiMAX 
(Thermo-Fisher) according to the manufacturer's instructions. 
3.3 Enzyme activity assay.
In order to evaluate NAGLU enzymatic activity in stable clones, 
pellets from 5×105 cells of each clone were collected, submitted to 10 
freeze thaw cycles, and clarified by centrifugation. The protein 
concentration of samples was measured by the Lowry method, while 
NAGLU enzymatic activity was measured as described by Marsh and 
Fensom (1985) using 4-methylumbelliferyl-Nacetyl-α-D-glucosaminide 
as a fluorogenic substrate. Enzymatic activity was normalized for total 
protein concentration and hydrolysis of 1 nmol of substrate per hour per 
milligram of protein was defined as one catalytic unit.
3.4 Fluorescence microscopy.
LysoTracker was used to label lysosomes (Chazotte B., 2011). 
Briefly, live-cell clones grown on a coverslip were incubated with 
LysoTracker probe for 1 h at 37 °C, washed with PBS, and fixed with 4% 
paraformaldehyde (PFA) solution in PBS. After washing with PBS, the 
coverslips were mounted with 1:1 PBS/glycerol solution, and observed 
under a confocal fluorescence microscope. Phalloidin was used to label 
cytoskeleton. After washing with PBS, cells were fixed with 4% PFA 
solution in PBS. After washing, cells were permeabilized with 0.1% 
Triton X-100 in PBS and then stained with 50 μg/ml fluorescent 
phalloidin conjugate, phalloidin-TRITC, in PBS for 1 h at room 
temperature. Then, nuclei were counterstained with DAPI for 1 h. After 
washing, the coverslips were mounted with 1:1 PBS/glycerol solution, 
and observed under a confocal fluorescence microscope. Images were 
collected by a laser-scanning microscope (LSM 510 META, Carl Zeiss 
Microimaging, Inc.) equipped with a planapo 63x oil immersion (NA 1.4) 
objective lens. 
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3.5 Coomassie staining.
Cells of each clone were washed in PBS, fixed with 4 % PFA 
solution in PBS for 1 h at room temperature, washed in PBS, and stained 
with Coomassie brilliant blue solution for 1 h at room temperature. Then, 
the cells were washed in distilled water, dried for 24 h, observed under a 
white light microscope, and photographed by a Nikon camera.
3.6 Quantitative RT-PCR.
Total RNA from H9C2 clones was extracted using Trizol reagent. 
500 ng of RNA were reverse transcribed for cDNA synthesis with Iscript 
RT-PCR system (Biorad). Reverse transcription of RNAs was followed 
by quantitative real-time polymerase chain reaction performed with the 
SYBR Green real time PCR master mix kit (FS Universal SYBR Green 
MasterRox/Roche Applied Science). The reactions were visualized by 
SYBR Green analysis (Applied Biosystem) on StepOne instrument 
(Applied Biosystem). Primers for gene analysis were the following:
ANP-Forward: 5'-GGAGCAAATCC CGTATACAGTGCG-3'
ANP-Reverse: 5'-GCGGAGGCATGACCTCATCTTCTAC-3'
BNP-Forward: 5'-CTGGGAAGTCCTAGCCAGTCTC-3'
BNP-Reverse: 5'CCGGAAGGCGCTGTCTTGAGACC-3'
MLC2V-Forward: 5'-GACCCAGATCCAGGAGTTCAAGG-3'
MLC2V-Reverse: 5'-CGAGGGCAGCAAACGTGTCCC-3'
NAGLU-Forward: 5'-GGCCAGGAGGCCATCTGGC-3'
NAGLU-Reverse: 5'-CCCAGGCCAGGAAGGCAGG-3'
S18-Forward: 5'-AAACGGCTACCACATCCAAG-3'
S18-Reverse: 5'CCTCCAATGGATCCTCGTTAA-3'
HB-EGF-Forward: 5'-GGACTACTGCATCCACGGAGAGT-3'
HB-EGF-Reverse: 5'-CCACCACAGCCAAGACGGTAGT-3'.
All standards and samples were assayed in triplicate. Thermal cycling 
was initiated with an initial denaturation at 95°C for 5 min. After this 
initial step, 40 cycles of PCR were performed. Each PCR cycle consisted 
of heating at 95°C for 30 sec for melting, 55°C for 30 sec for annealing 
and 72°C for 30 sec for the extension. To calculate the relative expression 
levels, we used the 2-ΔΔCT method (Livak K.J., et al., 2001). 
3.7 Western Blotting.
Cells were harvested in lysis buffer containing 50 mM Tris ph7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton-X-
100, 1 mM ß-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride, 
protease inhibitor cocktail tablet, 1 mM sodium orthovanadate, and 2.5 
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mM sodium pyrophosphate. The lysates were incubated for 30 min on ice, 
supernatants were collected and centrifuged for 10 min at 14,000 g. 
Protein concentration of protein extracts was measured by the Bradford 
assay. 25 or 50 µg/lane of total proteins were separated on SDS gels and 
transferred to nitrocellulose membranes. Membranes were treated with a 
blocking buffer (25 mM Tris, pH 7.4, 200 mM NaCl, 0.5% Triton X-100) 
containing 5% non-fat powdered milk for 1 h at room temperature. 
Incubation with the primary antibody was carried out overnight at 4 °C. 
After washings, membranes were incubated with the horseradish 
peroxidase- conjugated secondary antibody for 1 h at room temperature. 
Following further washings of the membranes, chemiluminescence was 
generated by ECL system. Densitometric analyses were performed using 
the NIH Image software (Bethesda, MD, USA).
3.8 Phospho-Receptor Tyrosine Kinase (Phospho-RTK) Array.
The phospho-RTK array (ARY001B, R&D Systems) which screens 
49 RTKs, was performed as following described. All reagents and 
samples were prepared according to manufacturer's instructions. 2.0 ml of 
array buffer 1 was pipetted into each well of the 4-well multi-dish as a 
blocking buffer; each array was placed into each well of the 4-well multi-
dish and incubated for 1 h at room temperature on a rocking platform 
shaker. Samples were prepared by diluting the desired quantity (50 μg of 
proteins) of cell lysates to a final volume of 1.5 ml with array buffer 1, 
and incubated overnight at 2-8°C on a rocking platform shaker pre-
blocked membranes. Each array was carefully placed into individual 
plastic containers with 20 ml of 1X washing buffer, and the 4-well multi-
dish was rinsed with deionized or distilled water and dried thoroughly. 
Each array was washed with 1X washing buffer for 10 min on a rocking 
platform shaker for three times. The anti-phospho-tyrosine-HRP detection 
antibody was finally diluted in 1X array buffer 2, and added to each array 
for 2 h at room temperature on a rocking platform shaker. Each array was 
washed three times with 2 ml of 1X washing buffer for 10 min on a 
rocking platform shaker. Membranes were incubated with 1 ml of the 
prepared Chemi Reagent Mix for 1 min. Membranes were exposed with 
an autoradiography film cassette to an X-ray film for 1-10 min. For the 
data analysis, the positive signal, seen on the developed film, was 
identified by placing the transparency overlay template on the array 
image and aligning it with the pairs of reference spots in the three corners 
of each array. Reference spots were included to align the transparency 
overlay template and to demonstrate that the array has been incubated 
with anti-phospho-tyrosine-HRP during the assay procedure.
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3.9 Statistical Analysis.
The data reported are expressed as the mean ± standard deviation 
(S.D.) of at least three independent experiments of equal design. 
Statistical significance was assessed by Student’s t-test. A value of P < 
0.05 was considered to be statistically significant. 
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4. RESULTS
4.1 NAGLU depletion causes lysosomal defects in H9C2  
cardiomyoblasts. 
To study the molecular mechanisms underlying the cardiac disease in 
MPS IIIB, we generated a cellular model of the disease in H9C2 
cardiomyoblasts by silencing NAGLU gene expression through a pool of 
three DNA plasmids carrying different sh-RNAs against NAGLU mRNA. 
Silenced clones (H9C2sh-NAGLU) showed a significant (70%) reduction 
of NAGLU catalytic activity compared to that of H9C2 stably transfected 
with a non-targeting sh-RNA (H9C2sh-CTR) (Figure 8).
Figure 8: Reduction of NAGLU enzymatic activity in H9C2 
stable silenced clones. NAGLU enzymatic activity in the extracts from 
selected NAGLU-depleted H9C2 stable clones (H9C2sh-NAGLU) and 
control H9C2 stably transfected with a non-targeting sh-RNA (H9C2sh- 
CTR). Cell lysates were assayed for protein content and enzyme activity 
as described in Materials and Methods. *P<0.05.
Accordingly, silenced clones (H9C2sh-NAGLU) showed a 
significant reduction of NAGLU mRNA and protein levels compared to 
that of H9C2sh-CTR clones (Figures 9). 
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Figure 9: Reduction of NAGLU mRNA and protein levels in 
silenced stable clones. (a) NAGLU mRNA expression levels in H9C2sh-
NAGLU and H9C2sh-CTR as measured by quantitative RT-PCR 
analysis. The amount of NAGLU mRNA was normalized with respect to 
the amount of 18S ribosomal RNA housekeeping gene. The data reported 
are the mean ± S.D. of 3 independent experiments. *P<0.05. (b) NAGLU 
protein levels in H9C2sh-CTR and H9C2sh-NAGLU as measured by 
Western blotting analysis. To monitor equal loading of protein, the blot 
was probed using anti- -actin antibody. The data reported are the mean 
± SD of three independent experiments of equal design. Densitometric 
analysis was performed, and the data obtained are reported on the 
histogram below. *P<0.05.
In MPS IIIB, the lack of NAGLU causes lysosomal accumulation of 
undegraded HS with consequent lysosomal enlargement. Therefore, we 
explored whether NAGLU silencing in H9C2 cardiomyoblasts induces 
aberrant lysosomal substrate accumulation. Staining with the LysoTracker 
probe showed more abundant and larger intracellular vacuoles in 
NAGLU-depleted H9C2 compared to H9C2sh-CTR (Figure 10a). 
Furthermore,, Western blotting analysis of the lysosomal associated 
membrane protein LAMP2 (Carlsson S.R.,et al., 1990) showed a 
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significant increase of LAMP2 protein levels in H9C2sh-NAGLU 
compared to H9C2sh-CTR (Figure 10b).
Figure 10: Lysosomal pathology in NAGLU silenced H9C2 
cardiomyoblasts. (a) Fluorescent staining of lysosomes in H9C2sh-
NAGLU and H9C2sh-CTR labeled by LysoTracker probe. In NAGLU-
depleted H9C2 more abundant and larger intracellular vacuoles than 
control H9C2 are visible. (b) LAMP2 protein expression levels in 
H9C2sh-NAGLU and H9C2sh-CTR as measured by Western blotting 
analysis. The amount of LAMP2 as measured by densitometry was 
normalized with respect to the amount of ß-actin. The data reported on the 
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histogram below are the mean ± S.D. of three independent experiments. 
*P<0.05. 
Furthermore, the staining with a fluorescent lectin that detecting 
sugars and glycoproteins containing β(1→4)-N-acetyl-D-glucosamine 
recognizes HS showed a more abundant intracellular and extracellular HS 
in the H9C2sh-NAGLU clones compared to H9C2sh-CTR where the 
main staining was observed exclusively in the Golgi apparatus (Figure 
11). 
Figure 11. Intracellular and extracellular accumulation of HS in 
NAGLU silenced H9C2 cardiomyoblasts. Fluorescent staining of HS in 
H9C2sh-CTR and H9C2sh-NAGLU labeled by lectin-FITC. Scale bars 
10 m. In NAGLU-depleted H9C2 an increased accumulation of HS on 
the cell membrane and in the periphery of the cells is detectable compared 
to control H9C2 clones.
Overal l , these data demonstrate that H9C2sh-NAGLU 
cardiomyoblasts show the HS storage abnormalities observed in MPS 
IIIB, thus suggesting that this cellular model represents a valuable tool to 
investigate the pathogenesis of cardiac disease in MPS IIIB. 
4.2 NAGLU deplet ion induces hypertrophy in H9C2  
cardiomyoblasts.
Firstly, we asked whether the loss of NAGLU might cause cellular 
hypertrophy in H9C2 cardiomyoblasts as already detected in NAGLU 
knockout mice (Schiattarella G.G., et al. 2015). To this purpose, the 
cellular cytoskeleton of H9C2sh-NAGLU and H9C2sh-CTR was labeled 
with fluorescent phalloidin. H9C2sh-NAGLU showed a morphological 
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expansion which is typical of an hypertrophic phenotype (Figure 12a), as 
also detected when clones were stained with Coomassie blue (Figure 
12b).
Figure 12. Hypertrophic phenotype of NAGLU silenced H9C2 
cardiomyoblasts. (a) Phalloidin staining of H9C2sh-CTR and H9C2sh-
NAGLU cellular cytoskeleton. Nuclei were counterstained with DAPI. 
Scale bars 10 m. Cell size enlargement was observed in NAGLU-
depleted H9C2 compared control H9C2. (b) Comassie staining shows 
cellular hypertrophy. Pictures are representative of three indipendent 
experiments.
The hypertrophic phenotype of H9C2sh-NAGLU was further 
confirmed by analyzing the expression of two markers of hypertrophy: 
atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) 
(Schiattarella G.G., et al. 2015). ANP and BNP mRNA levels were 
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significantly higher in H9C2sh-NAGLU than in control clones (Figure 
13). 
Figure 13: Expression levels of mRNAs coding for ANP and BNP 
hypertrophic mediators in H9C2sh-CTR and H9C2sh-NAGLU. The 
amount of ANP and BNP mRNA as measured by quantitative RT-PCR 
analysis was normalized with respect to the amount of 18S ribosomal 
RNA housekeeping gene. *P<0.05.
The differentiation capability under 1% FBS stimulation of H9C2 
cardiomyoblasts into cardiomyocytes was impaired as measured by 
MLC2v mRNA levels (Figure 14). All together these data indicate that 
the loss of NAGLU leads to cellular hypertrophy and differentiation 
defects. In addition, these results confirm the reliability of our MPS IIIB 
cell model to investigate the molecular events induced by NAGLU 
silencing in cardiac cells. 
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Figure 14. Impaired differentiation capability of NAGLU 
silenced H9C2 cardiomyoblasts. Expression levels of MLC2v mRNA in 
the presence and absence of FBS in H9C2sh-CTR and H9C2sh-NAGLU 
clones as detected by quantitative PCR. *P<0.05.
4.3 EGFR activation accounts for hypertrophy in NAGLU-depleted  
H9C2 cardiomyioblasts.
In order to investigate the molecular mechanisms responsible for 
lysosomal abnormalities and hypertrophic response induced by NAGLU 
silencing in H9C2 cardyomyoblasts, we performed a phospho- receptor 
tyrosine kinase (RTK) array on NAGLU-depleted H9C2 and H9C2sh-
CTR. Among 49 tested RTKs (Table 2), we detected the specific 
phosphorylation of EGFR in H9C2sh-NAGLU (Figure 15a). Similar 
result was obtained by Western blotting analysis of the phosphorylation 
levels of EGFR in NAGLU-depleted H9C2 that resulted to be 
significantly higher than control cells (Figure 15b). 
Table 2: Phospho-RTK array coordinates.
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Figure 15: EGFR activation in NAGLU silenced H9C2 
cardiomyoblasts. (a) p-RTK array showing the effect of NAGLU 
silencing on RTK phosphorylation. Cell lysates of H9C2 sh-CTR and 
H9C2 sh-NAGLU were applied (left panels) to p-RTK arrays. The 
chemiluminescent film images (right panels) are shown. The blue dots in 
the lower panels indicate the position of EGFR. (b) EGFR 
phosphorylation levels in H9C2 sh-NAGLU and H9C2 sh-CTR cells as 
measured by Western blotting analysis. To monitor protein loading, the 
upper blot was stripped and re-probed using anti-EGFR antibody. 
Densitometric analysis of the bands was performed and the data obtained 
are reported on the histogram below. *P<0.05 
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The involvement of EGFR activation in the hypertrophic response 
induced by NAGLU silencing in H9C2 cardiomyoblasts was confirmed 
by the observation that the treatment of H9C2sh-NAGLU with the 
specific EGFR inhibitor AG1478 (Levitzki A., et al., 1995) caused a 
signifcant reduction of ANP and BNP mRNA levels as compared to the 
untreated clones (Figure 16).  No effect of AG1478 treatment was 
observed on ANP and BNP mRNA levels in H9C2 sh-CTR cells.
Figure 16: EGFR inhibition impairs the hypertrophic response in 
NAGLU silenced H9C2 cardiomyoblasts. Expression levels of mRNA 
coding for ANP and BNP both in the absence and presence of AG1478 in 
H9C2sh-NAGLU and H9C2sh-CTR as measured by quantitative RT-PCR 
analysis. The amount of ANP and BNP mRNA was normalized with 
respect to the amount of 18S ribosomal RNA housekeeping gene. 
*P<0.05
Furthermore, the AG1478 treatment did not affect the cell size of 
H9C2 sh-CTR as measured by phalloidin staining (Figure 17, upper 
panels), whereas a significant reduction of the cell dimensions of 
NALGU-depleted H9C2 upon AG1478 treatment was detected (Figure 
17, lower panels). These results demonstrate that EGFR inhibition is able 
to rescue the hypertrophic phenotype of NALGUsilenced H9C2 
cardiomyoblasts. 
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Figure 17: Abrogation of the hypertrophic phenotype by 
EGFR inhibition in NAGLU silenced H9C2 cardiomyoblasts. 
Representative images of actin cytoskeleton stained with phalloidin of 
H9C2 sh-CTR and H9C2 sh-NAGLU, both untreated and treated for 24 h 
with 10 µM of AG1478. Scale bars: 10 µm. A significant reduction of cell 
size was observed in AG1478 treated NAGLU-depleted H9C2 (lower 
panels), while no effect was detected in H9C2 sh-CTR clones (upper 
panels).
To establish the EGFR contribution to MPS IIIB lysosomal storage 
disorder in cardiac cells, we measured LAMP2 lysosomal-membrane 
associated protein levels in H9C2sh-NAGLU and control clones in the 
presence of the EGFR inhibitor AG1478. AG1478 treatment was able to 
significantly reduce LAMP2 protein expression levels in NAGLU-
depleted cardiomyoblasts, whereas it did not influence LAMP2 protein 
levels in control clones (Figure 18a). Consistently, LysoTracker staining 
showed that H9C2sh-NAGLU treated with AG1478 have a reduced 
lysosome staining compared to untreated cells (Figure 18b).
These results definitely indicate that EGFR inhibition reduces both 
hypertrophy and lysosomal defects in NAGLU silenced H9C2 
cardiomyoblasts.
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Figure 18: Reduction of lysosomal pathology by EGFR inhibition 
in NAGLU silenced H9C2 cardiomyoblasts. (a) LAMP2 protein 
expression levels both in absence and presence of AG1478 in H9C2sh-
NAGLU and H9C2sh-CTR as measured by Western blotting analysis. 
The amount of LAMP2 as measured by densitometry was normalized 
with respect to the amount of β-actin. *P<0.05. B. Fluorescent staining of 
lysosomes in H9C2sh-NAGLU and H9C2sh-NAGLU treated with 10 μM 
of AG1478 labeled by LysoTracker probe. In the AG1478 treated clones, 
lysosome staining and cell size was reduced compared to the untreated 
clones. 
4.4 EGFR activation triggers ERK1/2 phosphorylation in NAGLU-
depleted H9C2 cardiomyoblasts.
The findings above reported prompted us to explore the EGFR signal 
transduction pathway contributing to the hypertrophic phenotype in 
NAGLU silenced cardiomyoblasts. Since previous evidence indicated that 
the phosphorylation of ERK1/2, a downstream target of EGFR, represents 
an essential regulator of the hypertrophic response (Bueno O.F. et al., 
2002), we evaluated the phosphorylation levels of ERK1/2 in NAGLU-
depleted rat cardiomyoblasts by Western blotting analysis. A significant 
increase in the phosphorylation levels of ERK1/2 in H9C2sh-NAGLU 
compared to control clones was observed (Figure 19a). Moreover, cell 
treatment with AG1478 resulted in a significant decrease of ERK1/2 
phosphorylation in H9C2sh- NAGLU (Figure 19b), indicating that 
ERK1/2 activation in NAGLU-depleted cardyomyoblasts is likely EGFR-
dependent.
35
Figure 19: Enhanced ERK1/2 phosphorylation in NAGLU 
silenced H9C2 cardiomyoblasts. (a) ERK1/2 phosphorylation levels in 
H9C2sh-NAGLU and H9C2sh-CTR as measured by Western blotting. To 
monitor equal loading of protein in the gel lanes, the upper blot was 
stripped and re-probed using anti-ERK1/2 antibody. Densitometric 
analysis of the bands was performed and the data obtained are reported on 
the histogram below. *P<0.05. (b) ERK1/2 phosphorylation levels in 
H9C2sh-NAGLU and H9C2sh-CTR in the absence and in the presence of 
AG1478  as measured by Western blotting. To monitor protein loading of 
gel lanes, the upper blot was stripped and re-probed using anti anti-
ERK1/2 antibody. Densitometric analysis was performed and the data 
obtained are reported on the histogram below. *P<0.05.
Then, we evaluated the effect of PD98059, a selective inhibitor of the 
MEK/ERK pathway (Ng D.C., et al., 2001; Pavone L.M., et al., 2011) on 
ERK1/2 phosphorylation in H9C2sh-NAGLU and H9C2sh-CTR. The 
treatment of H9C2sh-NAGLU with, PD98059 caused a drastic reduction 
of ANP mRNA levels (Figure 20a), thus suggesting that ERK1/2 
phosphorylation is essential for the development of the hypertrophic 
phenotype. Furthermore, phalloidin staining of H9C2 sh-CTR and H9C2 
sh-NAGLU exposed to PD98059 showed that the inhibitor treatment did 
not affect cell size of H9C2 sh-CTR (Figure 20b, upper panels), whereas 
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it caused a significant reduction of the cell dimensions in H9C2 sh-
NAGLU compared to the untreated clones (Figure 20b, lower panels). 
Figure 20: Reduction of cell size enlargement by MEK/ERK 
inhibition in NAGLU silenced H9C2 cardiomyoblasts. (a) Expression 
levels of mRNAs coding for ANP in H9C2sh-NAGLU and H9C2sh-CTR, 
in the absence and presence of PD98059, as measured by quantitative RT-
PCR analysis. The amount of ANP mRNA was normalized with respect 
to the amount of 18S ribosomal RNA housekeeping gene. *P<0.05. (b) A 
significant reduction of cell size was observed in PD98059 treated 
NAGLU-depleted H9C2 (lower panels), while no effect was detected in 
H9C2 sh-CTR clones (upper panels).
4.5 NAGLU depletion in H9C2 cardiomyoblasts induces c-Src  
activation. 
A direct link between EGFR signaling and enhanced Src-family 
kinase activity has been established (Biscardi J.S., et al., 1999). 
Therefore, we investigated the phosphorylation levels of c-Src in 
H9C2sh-NAGLU and control clones. A significant increase of c-Src 
phosphorylation was found in NAGLU-depleted H9C2 as compared to 
H9C2sh-CTR (Figure 21a). The treatment of H9C2sh-NAGLU with the 
EGFR inhibitor AG1478 did not reduce c-Src phosphorylation levels 
(Figure 21b), thus suggesting that c-Src phosphorylation represents an 
upstream event in EGFR activation following NAGLU depletion. 
37
Figure 21: c-Src activation in NAGLU depleted H9C2 
cardiomyoblasts. (a) c-Src phosphorylation levels in H9C2sh-NAGLU 
and H9C2sh-CTR as measured by Western blotting . To monitor protein 
loading of gel lanes, the upper blot was stripped and re-probed using anti-
c-Src antibody. Densitometric analysis of the bands was performed and 
the data obtained are reported on the histogram below. *P<0.05. (b) c-Src 
phosphorylation levels in H9C2sh-NAGLU and H9C2sh-CTR, in the 
absence and presence of AG1478 as measured by Western blotting. To 
monitor protein loading, the upper blot was stripped and re-probed using 
anti-c-Src antibody. Densitometric analysis was performed and the data 
obtained are reported on the histogram below. *P<0.05. 
Furthermore, Western blotting analysis showed that EGFR 
phosphorylation is reduced in the H9C2sh- NAGLU transfected with a 
dominant negative (DN) c-Src (Figure 22), indicating that EGFR 
phosphorylation in this MPS IIIB cellular model is mediated by c-Src.
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Figure 22: Reduction of EGFR phosphorylation by c-Src 
interfering in NAGLU depleted H9C2. EGFR phosphorylation levels in 
H9C2 sh-NAGLU and H9C2 sh-CTR cells transfected with DN c-Src as 
measured by Western blotting. The amount of EGFR phosphorylation as 
measured by densitometry was normalized with respect to the amount of 
ß-actin. *P<0.05. 
Subsequently, the involvement of c-Src activation in the hypertrophic 
phenotype of NAGLU-depleted cardiomyoblasts was evaluated by 
measuring ANP mRNA levels in H9C2sh-NAGLU transfected with DN 
or wild-type (WT) c-Src. A significant reduction of ANP mRNA levels 
was observed in H9C2sh-NAGLU in the presence of DN c-Src (Figure 
23a), whereas ANP mRNA levels strongly increased in the presence of 
WT c- Src (Figure 23b). By contrast, transfection with DN c-Src or WT c-
Src had no effect on ANP mRNA levels in H9C2sh-CTR. Overall, these 
results suggest that c-Src activation contributes to the hypertrophic 
response in NAGLU-depleted cardiomyoblasts by activating EGFR 
signaling. 
39
Figure 23: Reduction of the hypertrophic response by c-Src 
interfering causes in NAGLU depleted H9C2. (a) Expression levels of 
mRNAs coding for ANP in H9C2sh-NAGLU and H9C2sh-CTR 
transfected with DN c-Src as measured by quantitative RT-PCR analysis. 
The amount of ANP and BNP mRNA was normalized with respect to the 
amount of 18S ribosomal RNA housekeeping gene. *P<0.05. (b) 
Expression levels of mRNAs coding for ANP of in H9C2sh-NAGLU and 
H9C2sh-CTR transfected with WT c-Src, as measured by quantitative 
RT- PCR analysis. The amount of ANP and BNP mRNA was normalized 
with respect to the amount of 18S ribosomal RNA housekeeping gene. 
*P<0.05. 
4.6 NAGLU depletion in H9C2 cardiomyoblasts results in  
increased expression levels of heparin-binding EGF-like growth factor  
(HB- EGF)
Multiple evidence demonstrated that the progressive accumulation of 
HS proteoglycans (HSPGs) on the cell membrane and extracellular matrix 
contributes to the pathogenesis of MPS diseases (Watson H.A. et al., 
2014; Pan C. et al., 2005). The extracellular HSPGs can bind and regulate 
the activity of the EGFR ligand HB-EGF (Prince R.N. et al., 2010), and 
EGFR activation by HB-EGF plays a role in the hypertrophic signaling in 
cardiomyocytes (Yoshioka J., et al., 2005). Thus, we investigated by 
Western blotting analysis the expression levels of HB-EGF in in H9C2sh-
NAGLU and control cells. A significant increase of the expression levels 
of HB-EGF protein was detected in H9C2sh-NAGLU as compared to 
control clones (Figure 24). 
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Figure 24: Up-regulation of heparin-binding EGF-like growth 
factor (HB-EGF) in NAGLU silenced H9C2 cardiomyoblasts. HB-
EGF protein expression levels in H9C2sh-NAGLU and H9C2sh- CTR as 
measured by Western blotting. The amount of HB-EGF as measured by 
densitometry was normalized with respect to the amount of ß-actin. 
*P<0.05.
Furthermore, we investigated whether HB-EGF silencing by a 
specific siRNA result in the reduction of the EGFR induced hypertrophic 
response. Upon silencing of HB-EGF protein in H9C2sh-NAGLU (Figure 
25a), we detected a reduction of ANP mRNA levels compared to the 
same cells treated with a scrambled siRNA (Figure 25b). These findings 
suggest that NAGLU-deficient cardiomyoblasts develop a hypertrophic 
phenotype through a coordinated intracellular and extracellular EGFR 
activation via c-Src and HB-EGF, respectively. 
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Figure 25: Reduction of the hypertrophic response by silencing of 
HB-EGF in NAGLU silenced H9C2 cardiomyoblasts. (a) Silencing of 
HB-EGF protein in H9C2sh-NAGLU and H9C2sh- CTR as measured by 
Western blotting. The amount of HB-EGF as measured by densitometry 
was normalized with respect to the amount of ß-actin. *P<0.05. (b) 
Expression levels of mRNAs coding for HB-EGF and ANP in H9C2sh-
NAGLU transfected with HB-EGF siRNA and CTR siRNA as measured 
by quantitative RT- PCR analysis. The amount of HB-EGF and ANP 
mRNAs were normalized with respect to the amount of 18S ribosomal 
RNA housekeeping gene. *P<0.05. 
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5. DISCUSSION
In MPS IIIB disease, NAGLU deficiency leads to the accumulation 
of abnormal levels of HS in the lysosomes of the cells as well as in the 
extracellular matrix which accounts for a number of pathologic events 
affecting various tissues and organs, including brain, liver, spleen, kidney, 
and heart (Ballabio A., et al., 2009). Indeed, both during development and 
adult life, HS, which is a component of the cell surface and extracellular 
matrix-associated proteoglycans, plays crucial roles in the regulation of 
many physiological processes due to its property to bind and interact with 
signaling proteins, morphogens, growth factors, and other critical 
molecules (Iozzo R.V., et al. 2015; Pan C., et al., 2005; Bernfield M., et 
al., 1999; Kim S.H. et al., 2011). The extracellular accumulation of HS 
has been shown to impair fibroblast growth factor 2 (FGF-2) receptor 
binding and signaling in cells derived from MPS I patients (Pan C. et al., 
2005). Here, we provide the first evidence that abnormal HS 
accumulation in a MPS IIIB cellular model is associated with the 
activation of EGFR signaling resulting in a hypertrophic phenotype.
The NAGLU-depleted cellular model generated by us fully 
represents the MPS IIIB lysosomal phenotype, showing lysosomal 
enlargement and cellular vacuolization. Furthermore, the increased levels 
of ANP and BNP mRNA in NAGLU-depleted cardiomyoblasts 
demonstrate that NAGLU silencing in H9C2 reproduces the hypertrophic 
phenotype previously detected in the cardiac tissues of NAGLU knock 
out mice (Schiattarella G.G., et al., 2015). Evidence exists about the 
involvement of EGFR in the onset of cardiac hypertrophy (Ai W. et al., 
2010; Esposito G., et al., 2011). In this study, a phospho- RTK array 
showed the specific activation of EGFR in NAGLU-depleted 
cardiomyoblasts. Treatment of NAGLU-depleted H9C2 with the selective 
EGFR inhibitor AG1478 strongly reduced the levels of ANP and BNP 
mRNA. The inhibition of EGFR activation by AG1478 also resulted in 
the reduction of lysosomal defects in NAGLU-depleted cardiomyoblasts. 
These data suggest an active role of EGFR in the cellular events 
downstream HS accumulation, including those effects that lead to cardiac 
hypertrophy in MPS IIIB disease.
Although the pathogenesis of cardiac hypertrophy involves a number 
of complex molecular mechanisms (Heineke J., et al., 2006), the 
MEK1/ERK1/2 pathway plays a central role in the regulation of the 
cellular processes that lead to cardiac hypertrophy (Bueno O.F. et al., 
2002). Moreover, the major actors of cardiac hypertrophy including ERKs 
and JNKs are activated by EGFR (Heineke J. et al., 2006; Duquesnes N., 
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et al., 2009). Accordingly to the above evidence, in NAGLU-depleted 
cardiomyoblasts we found increased ERK1/2 phosphorylation, which was 
inhibited by the EGFR inhibitor AG1478. Furthermore, inhibition of 
ERK1/2 phosphorylation with the MEK/ERK inhibitor PD98059 strongly 
reduced ANP mRNA expression levels in NAGLU-depleted 
cardiomyoblasts. These results clearly demonstrate that the hypertrophic 
phenotype detected in the MPS IIIIB cellular model is associated with 
ERK1/2 phosphorylation promoted by EGFR activation.
Commonly, EGFR activation occurs either by binding with ligands 
such as EGF and HB-EGF, or by transactivation. Cellular Src (c-Src), a 
membrane-associated tyrosine kinase, is required for many EGFR-
mediated cellular functions (Biscardi J.S. et al., 1999, Luttrell L.M., et al., 
1997; Wu W.J., et al., 2003). The interactions between EGFR and c-Src 
are bi-directional, and their consequence is an enhanced phosphorylation 
of specific substrates. In this study, we found increased c-Src 
phosphorylation levels in NAGLU- depleted cardiomyoblasts compared 
control cells, and c-Src phosphorylation resulted to be unaffected by 
treatment with AG1478. Furthermore, our investigations showed that both 
EGFR phospshorylation and ANP mRNA expression levels are 
respectively down-regulated or up-regulated by transfecting H9C2sh-
NAGLU cardiomyoblasts with DN or WT c-Src. These findings indicate 
that in NAGLU-depleted cardiomyoblasts c-Src phosphorylation mediates 
EGFR activation with subsequent signaling leading to the hypertrophic 
phenotype. 
Together with the activation of EGFR by c-Src, we also found in our 
cellular model the up-regulation of the EGFR ligand HB- EGF. The 
progressive accumulation of HSPGs on the cell membrane and 
extracellular matrix contributes to the pathogenesis of MPS diseases 
(Watson H.A, et al. 2014; Pan C., et al., 2005; Ballabio A. et al., 2009). 
Extracellular HSPGs may sequester soluble secreted growth factors and 
facilitate their binding to the cognate receptors, thus activating receptor 
signaling (Iozzo R.V. et al., 2015; Bernfield M. et al. 1999; Faye C., et 
al., 2009). Moreover, HSPGs may also interact with growth factors 
anchored to the cell surface via a trans-membrane domain, and especially 
those belonging to the EGFR-ligand family, which include HB-EGF 
(Prince R.N., et al., 2010). The proteolytic cleavage of the anchored form 
of HB-EGF, proHB-EGF, at the extracellular domain gives rise to the 
soluble form of HB-EGF. It has been demonstrated that HB-EGF plays an 
important role in cardiac heart development (Iwamoto R., et al., 2010), 
and hypertrophy (Yoshioka J., et al., 2005; Lee K.S., et al., 2011). 
Angiotensin II-mediated transactivation of EGFR appears to involve Src- 
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mediated MMP-activated release of HB-EGF (Eguchi S., et al., 2001). 
Transactivation of RTKs by G protein-coupled receptors (GPCRs) is a 
common pathway for transmission of reactive oxygen species (ROS)- 
sensitive signals, and interaction between GPCRs and RTKs may occur 
either in a ligand- independent manner involving membrane associated 
non-receptor tyrosine kinases, such as c-Src, or through the activation of 
metalloproteases (MMPs) which induce the release of RTK ligands (Little 
P.J., et al., 2013; Cattaneo F., et al., 2014) such as HB-EGF. Indeed, the 
increased HB-EGF expression levels and the reduction of the 
hypertrophic response following HB-EGF silencing observed in NAGLU-
depleted cardiomyoblasts suggest that in the MPS IIIB cellular model 
HB-EGF plays a part in EGFR activation and subsequent signaling 
leading to hypertrophy. Based on our findings and the literature we 
unraveled the signaling mechanism by which NAGLU silencing, 
lysosomal defects and the excess of extracellular HSPGs promote 
hypertrophy through c-Src and HB-EGF-mediated activation of EGFR 
linking to ERK1/2 pathway.
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6. CONCLUSION AND PERSPECTIVES
Until recently, no effective approved therapy for MPS IIIB is 
available. Substrate reduction therapy based on the use of small molecules 
with inhibitory activity of GAG synthesis has been tested as a possible 
treatment for MPS diseases. In particular, genistein, a compound 
belonging to the family of isoflavones, was shown to decrease GAG 
synthesis in fibroblasts from MPS I, II, IIIA and IIIB (Piotrowska E., et 
al., 2006). Indeed, genistein is able to inhibit the kinase activity of EGFR 
required for the regulation of the activity of particular transcription 
factors involved in GAG synthesis (Moskot M., et al., 2014). However, 
genistein only partially ameliorates the clinical symptoms of MPS III 
patients (De Ruijter J., et al., 2012). Our findings highlight the central role 
of EGFR activation in the hypertrophic phenotype and lysosomal 
pathology related to cardiac disease in MPS IIIB. In particular, our study 
demonstrates that NAGLU deficiency, leading to abnormal accumulation 
of either intracellular or extracellular HS, triggers c-Src activation and 
HB-EGF up-regulation, both promoting EGFR signaling activation. The 
EGFR downstream activation of RK signaling cascade finally results in 
hypertrophy. 
In conclusion, the results of our study not only contribute to a better 
understanding of the molecular mechanisms underlying cardiac disease in 
MPS IIIB, but also provide novel clues for EGFR pathway targeting-
based approaches for MPS IIIB as well as for other MPS diseases. 
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